Drugs / ORL-1M
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03404869 | Mar 2015 → Jun 2019 | congenital disorder of glycosylation, type Ibb | Orpha Labs | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ORL-1M | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03404869 ↗ |
| Known as | D-mannose | “ORL-1M - D-mannose” NCT03404869 ↗ |
| Route | Oral | “Oral ORL-1M” NCT03404869 ↗ |